Anxiety Disorders And Depression Treatment Market

Anxiety Disorders And Depression Treatment Market Overview (2023 to 2033)

The global Anxiety Disorders and Depression Treatment Market was valued at around USD 11.2 billion in 2021. With a projected CAGR of 3.4% for the next ten years, the market is likely to reach a valuation of nearly USD 16.1 billion by the end of 2032.In the upcoming years, market growth is anticipated to be accelerated by efforts made jointly by pharmaceutical firms, NGOs, mental health groups, and government initiatives to raise public awareness.

Report Attributes	Details
Anxiety Disorders And Depression Treatment Market Size (2021A)	USD 11.2 billion
Estimated Market Value (2022E)	USD 11.5 billion
Forecasted Market Value (2032F)	USD 16.1 billion
Global Market Growth Rate (2022 to 2032)	3.4% CAGR
United States Growth Rate (2022 to 2032)	3.2% CAGR
Key Companies Covered	Pfizer Inc.; H. Lundbeck A/S; Glaxo SmithKline pharmaceuticals ltd.; Merc Co Inc.; Eli Lilly & Company

Future Market Insights’ analysis reveals that in 2022 revenue through the Anxiety Disorders and Depression Treatment Market is estimated at USD 11.5 billion. Worldwide, due to the enormous financial and emotional strain on people, families, and society as a whole, mental health illnesses are becoming more prevalent among adults.

The WHO estimates that the cost of mental health issues in affluent nations ranges from 3% to 4% of GDP. As a result, the government's goal of lessening the financial burden of these disorders is likely to spur product demand and ensure prompt management of anxiety and depression.

Sales Analysis of Anxiety Disorders and Depression Treatment Market from 2015 to 2021 Vs Market Outlook for 2022 to 2032

The global market for Anxiety Disorders and Depression Treatment Market expanded at a CAGR of 2.7% from 2015 to 2021. Around 284 million people worldwide suffer from anxiety, yet only 36% of them seek therapy, according to MindMed research.

Sales of anxiety and depression-related disease products and clinical trials are increasing in the global market because of the demand for appropriate management of these disorders as well as strong outreach activities. The United States will continue to be the largest user of anxiety disorder and depression treatment products throughout the analysis period accounting for over USD 1.5 billion absolute dollar opportunity in the coming 10-year period.

How are key drivers going to affect the Anxiety Disorders and Depression Treatment Market?

Strong support for Research and Development (R&D) funding from the government and international healthcare organizations has spurred the revenue growth of the anxiety disorders and depression treatment market. Around 76 thousand grants for mental health were active between 2015 and 2020 from 345 funders in 38 nations.

About 5% of all registered grants and 4% of the overall research spending, or USD 18.5 billion, were related to mental health. With 89%, high-income nations received the majority of investments while the United States provided 39% of all grants. These investments are probably expected to help the market for treating anxiety disorders and depression in several ways.

Globally, patient care for mental health diseases is being enhanced through research and development. There are now more candidates for the treatment of anxiety disorders and depression in the pipeline owing to innovative research that has resulted in combination therapies using novel or existing medication molecules. For instance, the USA FDA recently approved LY03005, an antidepressant medicine manufactured by Luye Pharma.

What are the restraints to the growth of the Anxiety Disorders and Depression Treatment Market?

High drug dosages used to treat damaged neurological cells typically cause harm to healthy cells in the body. Many people experience a variety of negative effects as a result of these, including weight gain, impaired vision, nausea, dizziness, and others.

As a result, these side effects from anxiety and depression medications are having a detrimental impact on the demand for therapy, and the unavailability of resources available is another issue impeding market expansion. For instance, according to WHO research, between 44% and 70% of patients in industrialized countries do not obtain treatment, whereas in developing countries the difference is significantly greater and is close to 90%.

Region-wise Insights

In what ways does the Anxiety Disorders and Depression Treatment Market in North America have a bright future?

Due to the availability of numerous branded formulations impacting the market dynamics, North America accounts for the largest market share of anxiety disorders and depression treatment accounting for over 45%. As a result of the present pandemic, the demand for therapies for anxiety disorders and depression has increased.

For instance, according to Bloomberg, the prescription rate for the anti-anxiety medication Zoloft increased by 12% in March 2020. Lockdowns, financial hardships, and a lack of physical contact have been cited as the main causes of a significant rise in depression and anxiety cases in North America.

Country-wise Insights

The USA Anxiety Disorders and Depression Treatment Market Analysis

The United States will account for USD 5.6 billion of the global Anxiety Disorders and Depression Treatment Market by 2032. Anxiety Disorders and Depression Treatment Market growth in the USA from 2015 to 2021 was estimated at 2.3% CAGR.

Researchers from Boston University found that half of the adults polled in the USA in September 2020 showed some symptoms of depression, such as feelings of helplessness and failure. These alarming statistics promise a further higher market for anxiety disorders and depression treatment market in the country.

The United Kingdom Anxiety Disorders and Depression Treatment Market Analysis

The anxiety Disorders and Depression market in the United Kingdom are expected to reach a valuation of USD 665.5 million by 2032. The market in the country is projected to gross an absolute dollar opportunity of USD 141.2 million from 2022 to 2032 and register a CAGR of 2.4%.

Japan Anxiety Disorders and Depression Treatment Market Analysis

The market in Japan is expected to garner an absolute dollar opportunity of USD 151.8 million in 2022. The market in the country is expected to reach a valuation of USD 932.2 million by 2032, growing at a CAGR of 1.8% from 2022 to 2032.

South Korea Anxiety Disorders and Depression Treatment Market Analysis

The market in South Korea is expected to expand at a CAGR of 1.4% from 2022 to 2032. The market is expected to swell at an absolute dollar opportunity of USD 77.2 million from 2022 to 2032. By 2032, the market in the country is likely to reach a valuation of USD 566.8 million.

Category-wise Insights

Why is depression taking center stage in the global Anxiety Disorders and Depression Treatment Market?

The market growth through the depression segment expanded at a CAGR of 2.4% from 2015 to 2021. According to WHO, depression affects an estimated 3.8% of the world's population, including 5% of adults and 5.7% of persons over the age of 60.

Suicide can result from depression at its worst. Every year, suicide claims the lives of more than 700 thousand people. For people aged 15 to 29, suicide is the fourth most common cause of death. More than 75.0% of people in low- and middle-income countries do not obtain treatment for mental problems despite the fact that there are well-established, efficient treatments.

Competitive Landscape

Companies that offer treatment for anxiety disorders and depression frequently form joint ventures, buy sister companies, and work to obtain the FDA to approve their treatments. There has also been a significant investment in R&D for some cutting-edge products.

The key companies operating in the Anxiety Disorders and Depression Treatment Market include Pfizer Inc, H. Lundbeck A/S, Glaxo SmithKline pharmaceuticals ltd, Merck & Co., Inc, Eli Lilly & Company, AstraZeneca, H. Lundbeck A/S, Bristol-Myers Squibb, Johnson & Johnson, AbbVie Inc., Sanofi, Novartis AG, Forest Laboratories, Inc., Alembic pharma, Janssen Pharmaceutical N.V., and Cadent Therapeutics.

Some of the recent developments by key providers of the Anxiety Disorders and Depression Treatment Market are as follows:

• In July 2021, Desipramine hydrochloride tablets USP, 10 mg, 25 mg, 50 mg, 75 mg, 100 mg, and 150 mg were approved by the US FDA for the treatment of depression.
• In May 2021, the PALISADE-a phase 3 trials, a randomized, double-blind, placebo-controlled research to assess the efficacy and safety of PH94B for the acute treatment of anxiety in people with a social anxiety disorder, was launched as part of VisataGen Therapeutics Inc.'s PALISADE Phase-3 clinical program (SAD).
• In November 2020, in order to aid patients with treatment-resistant major depressive disorder, Janssen Pharmaceutical N.V. worked with the mental healthcare provider Koa Health to conduct research on how to give digital cognitive behavioral therapy alongside pharmacological treatment.
• In August 2020, the USA Food And Drug Administration (FDA) approved an application to add intranasal SPRAVATO, a nasal spray, with an oral antidepressant to Treat depressive symptoms in adults with major depressive disorder and abrupt suicidal ideation or behavior. This was announced by Janssen Pharmaceuticals N.V.
• In June 2020, an agreement was reached between Neurocrine Bioscience, Inc. and Takeda Pharmaceutical Company Limited to work together on developing new treatments for psychiatric diseases.
• In December 2020, Novartis announced that it would acquire Cadent Therapeutics for up to USD 770 million in total consideration. With the acquisition, Novartis will be able to take advantage of Cadent's full neuroscience portfolio and increase its market share in the field of mental health.
• In December 2020, a merger deal was signed by Big Rock Partners Acquisition Corp. and NeuroRx, a company developing cutting-edge treatments for COVID-19 and bipolar illness.
• In December 2020, the European Medicines Agency (EMA) accepted H. Lundbeck A/submission S's for Vyepti for assessment of the Marketing Authorization Application (MAA). The application asks for permission to make Vyepti available to European residents who suffer from migraine and are qualified for preventative therapy. The goal of Vyepti is to stop calcitonin gene-related peptide (CGRP) from interacting with its receptor, which will stop migraine attacks.

Similarly, recent developments related to companies providing services for Anxiety Disorders and Depression Treatment have been tracked by the team at Future Market Insights, which is available in the full report.

Key Segments Covered in Anxiety Disorders and Depression Treatment Market Survey

By Drug Class:

• Antidepressants
• Anxiolytics
• Anticonvulsants
• Noradrenergic Agents
• Atypical Antipsychotics

By Indication:

• Anxiety
• Depression

By Distribution Channel:

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

By Region:

• North America
• Latin America
• Europe Anxiety
• Asia Pacific Anxiety
• Middle East & Africa

Frequently Asked Questions

How much is the global Anxiety Disorders and Depression Treatment Market currently worth?

The global Anxiety Disorders and Depression Treatment Market was valued at USD 11.2 billion in 2021.

What is the Anxiety Disorders and Depression Treatment Market Forecast through 2032?

The Anxiety Disorders and Depression Treatment Market is set to witness a growth rate of 3.4% over the forecast period and be valued at USD 16.1 billion by 2032.

At what rate did demand for Anxiety Disorders and Depression Treatment Market increase over the past 6 years?

The Anxiety Disorders and Depression Treatment Market expanded by CAGR 2.7% from 2015 through 2021.

Who are the key players shaping the Anxiety Disorders and Depression Treatment Market?

The key players in the Anxiety Disorders and Depression Treatment Market are Pfizer Inc, H. Lundbeck A/S, Glaxo Smithkline Pharmaceuticals Ltd, Merc Co Inc, Eli Lilly & Company.

Who are the top 5 countries driving the highest sales in the Anxiety Disorders and Depression Treatment Market?

United States, United Kingdom, China, Japan, and South Korea are expected to drive the most sales growth in the Anxiety Disorders and Depression Treatment Market.

What is the China market outlook for Anxiety Disorders and Depression Treatment?

The Anxiety Disorders and Depression Treatment Market in China account for USD 665.6 Million of the global market share by end of the forecast year.

Which country has the largest market share of the Anxiety Disorders and Depression Treatment Market?

The United States held the largest market share of the Anxiety Disorders and Depression Treatment Market with USD 1.5 billion of absolute dollar opportunity.